Resverlogix: The Future of Drug Development

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-bas …

October 4, 2021
Request Investor InfoRequest Investor Info
Resverlogix

Developing safe, epigenetic therapeutics for people suffering from chronic illnesses

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.

For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.

Investing
stock market

You might also like

Canada’s Critical Minerals Push Could Drive the Next Wave of Energy Investment: Lance Mortlock, EY Canada
May 25, 2026

Canada’s Critical Minerals Push Could Drive the Next Wave of Energy Investment: Lance Mortlock, EY Canada

This is some text inside of a div block.
Canada’s Defense Spending Surge Could Reshape Industry Growth: EY Canada
May 25, 2026

Canada’s Defense Spending Surge Could Reshape Industry Growth: Jeff Hamilton, EY Canada

This is some text inside of a div block.
BTV Visits: Calian Group, NevGold, Verdera, Jindalee, & Titan Mining
Metals & Mining
May 25, 2026

BTV Visits: Calian Group, NevGold, Verdera, Jindalee, & Titan Mining

This is some text inside of a div block.
Subscribe and receive the investor Info